A photo of Alexander Vinks.

Alexander "Sander" A. Vinks, PharmD, PhD, FCP

  • Director, Division of Clinical Pharmacology
  • Scientific Director, Pharmacy Research, Research in Patient Services
  • Professor, UC Department of Pediatrics
  • Adjunct Professor of Pharmacology



I have been a researcher for more than 37 years and began working at Cincinnati Children's in 2000. My research is in pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation, systems pharmacology, physiologically based pharmacokinetics (PBPK) and pharmacogenetics/genomics. I am also interested in applying population and simulation methods to inform pediatric clinical trial design and therapeutic drug management by implementing model-informed precision dosing strategies and clinical decision support tools.

I became interested in this research early in my career when I directed a therapeutic drug monitoring and clinical toxicology laboratory. I realized that every patient is different in terms of how the body metabolizes drugs and how patients very much differ in their response to medications. The ongoing paradox is that the drug development process is based on selecting a safe and effective dose for the 'average' patient. My program's goal is to promote the implementation of precision medicine and individualized precision dosing, tailoring doses to individual needs. We also work to predict how patients will respond to medications using pharmacogenetics/genomics to select the best drug and corresponding dose.

Some of our notable work includes implementing the Genetic Pharmacology Service (GPS) in 2004 and the formation of the successful startup company AssureX (now Myriad Genetics) that resulted from the GPS initiative. In recent years we have been successful in the development and implementation of electronic health records (EHR) integrated clinical decision support platforms for model-informed precision dosing. These achievements cover a variety of drugs and indications, including neonatal pain management with morphine (NeoRelief), precise hydroxyurea therapy in sickle cell anemia (HdxSim), optimizing infliximab, adalimumab and vedolizumab dosing in patients with inflammatory bowel disease (RoadMAB) and personalized reduced-intensity conditioning with melphalan in patients undergoing hematopoietic stem cell transplantation.

For additional information, please see: Personalized Medicine through Model-informed Precision Dosing: What's Here – What's Near? and Genomics Ushers in Era of Personalized Medicine.

I am honored to have received many awards and appointments throughout my career, including:

  • The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Mentor Award (2020)
  • The Cincinnati Children's Research Foundation Senior Mentoring Award (2017)
  • The Cincinnati Children's Research Foundation Endowed Chair (2015)
  • The International Association Therapeutic Drug Monitoring & Clinical Toxicology Charles E. Pippenger Award (2015)
  • President, International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) (2009-2011)
  • Executive Board Member, American Board of Clinical Pharmacology, Inc. (2008-2020)
  • Fellow, American College of Clinical Pharmacology (2002-present)
  • Board certification in clinical pharmacology (2001)

I have presented my research as an invited speaker at 260 national and international conferences. I have published over 250 peer-reviewed manuscripts, 260 abstracts, 20 book chapters and invited reviews, and I am co-editor of a book on the Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (over 38,000 chapter downloads). I’m on the editorial board of several journals, and I am an associate editor of Clinical Pharmacology & Therapeutics.

Certification: American Board of Clinical Pharmacology, 2001.

PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.

PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.

MS: Pharmacology, University of Toronto, Toronto Canada, 1983.

MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.

Research Areas

Clinical Pharmacology, Reproductive Sciences, Pharmacy


β-lactam precision dosing in critically ill children: Current state and knowledge gaps. Tang Girdwood, S; Pavia, K; Paice, K; Hambrick, HR; Kaplan, J; Vinks, AA. Frontiers in Pharmacology. 2022; 13.

Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Colman, RJ; Samuels, A; Mizuno, T; Punt, N; Vinks, AA; Minar, P. Inflammatory Bowel Diseases. 2022.

Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Dong, M; Sadaf, A; Vinks, AA; Ware, RE; Quinn, CT. Blood. 2022; 140:8256-8257.

Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Dong, M; Good, A; Vinks, AA; Ware, RE; McGann, PT. Blood. 2022; 140:8168-8169.

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; et al. Clinical Gastroenterology and Hepatology. 2022.

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Cardiovascular Drugs and Therapy. 2022; 36:589-604.

A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. van Hoogdalem, MW; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Pharmacology and Therapeutics. 2022; 234.

Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. Mizuno, T; Dong, M; Taylor, ZL; Ramsey, LB; Vinks, AA. British Journal of Clinical Pharmacology. 2022; 88:1418-1426.

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, AA; Jodele, S. Blood Advances. 2022; 6:1454-1463.

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; et al. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

From the Blog

Personalized Medicine through Model-informed Precision Dosing
Tools for Science

Personalized Medicine through Model-informed Precision Dosing

Alexander "Sander" A. Vinks, PharmD, PhD, FCP7/1/2019

Genomics Ushers in Era of Personalized Medicine
Mind Brain Behavior

Genomics Ushers in Era of Personalized Medicine

Alexander "Sander" A. Vinks, PharmD, PhD, FCP6/30/2019